ARRANON (nelarabine)
T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
GSK
Indication
T-cell lymphoblastic lymphoma
T-cell lymphoblastic lymphoma is an aggressive precursor lymphoid neoplasm characterized by the malignant proliferation of immature T-cell lymphoblasts. Read more about T-cell lymphoblastic lymphoma
13 drugs 13 manufacturers
Drugs that treat it
Common T-cell lymphoblastic lymphoma therapies.
ARRANON (nelarabine)
T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
Novartis Pharmaceuticals
NELARABINE
PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
SAGENT PHARMACE
NELARABINE
PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
DR.REDDY'S LAB
NELARABINE
PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
ALEMBIC PHARMAC
NELARABINE
PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
ZYDUS PHARMACEU
NELARABINE
PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
MEITHEAL PHARMA
NELARABINE
PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
NOVADOZ PHARMAC
NELARABINE
PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
SHORLA PHARMA I
Filter & compare in the drug finder →Opens the drug finder with T-cell lymphoblastic lymphoma preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonT-cell lymphoblastic lymphoma is an aggressive precursor lymphoid neoplasm characterized by the malignant proliferation of immature T-cell lymphoblasts.
The disease most commonly affects children, adolescents, and young adults, exhibiting a pronounced male predominance.
Biologically continuous with T-cell acute lymphoblastic leukemia, it is distinguished clinically by primary nodal or extranodal mass lesions—classically an anterior mediastinal mass involving the thymus and regional lymph nodes—with less than 25% blast involvement in the bone marrow.
Pathophysiologically, the neoplastic cells express immature T-lineage markers such as terminal deoxynucleotidyl transferase (TdT) and CD3, frequently accompanied by recurrent oncogenic drivers including NOTCH1 mutations.
- nih.gov
T-cell lymphoblastic lymphoma is an aggressive precursor lymphoid neoplasm characterized by the malignant proliferation of immature T-cell lymphoblasts The disease most commonly affects children, adolescents, and young adults, exhibiting a pronounced male predominance Biologically continuous with T-cell acute lymphoblastic leukemia, it is distinguished clinically by primary nodal or extranodal mass lesions—classically an anterior mediastinal mass involving the thymus and regional lymph nodes—wit...
- nih.gov
T-cell lymphoblastic lymphoma is an aggressive precursor lymphoid neoplasm characterized by the malignant proliferation of immature T-cell lymphoblasts
- cancer.gov
The disease most commonly affects children, adolescents, and young adults, exhibiting a pronounced male predominance Biologically continuous with T-cell acute lymphoblastic leukemia, it is distinguished clinically by primary nodal or extranodal mass lesions—classically an anterior mediastinal mass involving the thymus and regional lymph nodes—with less than 25% blast involvement in the bone marrow
- nih.gov
Biologically continuous with T-cell acute lymphoblastic leukemia, it is distinguished clinically by primary nodal or extranodal mass lesions—classically an anterior mediastinal mass involving the thymus and regional lymph nodes—with less than 25% blast involvement in the bone marrow
Personalize your experience
Follow T-cell lymphoblastic lymphoma and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.